Insulet Co. (NASDAQ:PODD) Shares Purchased by Natixis Advisors LLC

Natixis Advisors LLC increased its stake in Insulet Co. (NASDAQ:PODD) by 33.8% during the fourth quarter, HoldingsChannel.com reports. The fund owned 44,371 shares of the medical instruments supplier’s stock after buying an additional 11,210 shares during the period. Natixis Advisors LLC’s holdings in Insulet were worth $11,584,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of PODD. Frank Rimerman Advisors LLC purchased a new position in Insulet in the 4th quarter worth about $220,000. Commonwealth Equity Services LLC lifted its position in shares of Insulet by 3.1% in the 4th quarter. Commonwealth Equity Services LLC now owns 16,665 shares of the medical instruments supplier’s stock valued at $4,351,000 after acquiring an additional 508 shares in the last quarter. Skandinaviska Enskilda Banken AB publ lifted its position in shares of Insulet by 203.8% in the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 44,875 shares of the medical instruments supplier’s stock valued at $11,820,000 after acquiring an additional 30,102 shares in the last quarter. Great Lakes Advisors LLC boosted its stake in Insulet by 34.5% in the 4th quarter. Great Lakes Advisors LLC now owns 3,478 shares of the medical instruments supplier’s stock worth $908,000 after purchasing an additional 893 shares during the period. Finally, Sequoia Financial Advisors LLC lifted its holdings in shares of Insulet by 2.4% in the fourth quarter. Sequoia Financial Advisors LLC now owns 2,170 shares of the medical instruments supplier’s stock valued at $566,000 after purchasing an additional 50 shares in the last quarter.

Analysts Set New Price Targets

Several brokerages recently issued reports on PODD. Piper Sandler increased their price objective on Insulet from $285.00 to $310.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Canaccord Genuity Group increased their target price on shares of Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Royal Bank of Canada began coverage on shares of Insulet in a report on Thursday, March 6th. They set an “outperform” rating and a $340.00 price target on the stock. Stifel Nicolaus increased their price objective on Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a report on Friday, February 21st. Finally, Wells Fargo & Company raised their price objective on shares of Insulet from $305.00 to $322.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat, Insulet has a consensus rating of “Moderate Buy” and an average price target of $292.06.

Insulet Trading Up 2.1 %

Shares of Insulet stock opened at $265.82 on Thursday. The company has a market cap of $18.67 billion, a price-to-earnings ratio of 45.91, a PEG ratio of 3.62 and a beta of 1.29. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $289.46. The company’s fifty day simple moving average is $272.21 and its 200-day simple moving average is $256.19. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The business had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. As a group, sell-side analysts expect that Insulet Co. will post 3.92 EPS for the current year.

Insider Activity

In other news, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the sale, the executive vice president now directly owns 11,383 shares in the company, valued at approximately $3,187,240. The trade was a 52.13 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.47% of the stock is currently owned by company insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.